Skip to main content
SpringerLink
Log in

Naltrexone: clinical data

  • Chapter
Drugs for Relapse Prevention of Alcoholism

Part of the book series: Milestones in Drug Therapy MDT ((MDT))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Altshuler HL Phillips PA, Feinhandler DA (1980) Alternation of enthanol self-administration by naltrexone. Life Sciences 26: 679–688

    Article  PubMed  CAS  Google Scholar 

  2. Volpicelli JR, Alterman AI, Hayashida M, O’Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry 49: 876–880

    PubMed  CAS  Google Scholar 

  3. Volpicelli JR, O’Brien CP, Alerman AI, Hayashida M (1990) Naltrexone and the treatment of alcohol dependence: initial observations. In: LB Reid (ed.): Opioids, Bulimia, Alcohol Abuse and Alcoholism, Springer-Verlag, New York, 195–214

    Google Scholar 

  4. O’Malley SS, Jaffe, AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992) Naltrexone and coping skills therapy for alcohol dependence: a control study. Arch Gen Psychiat 49: 881–887

    PubMed  CAS  Google Scholar 

  5. Harris KM, DeVries A, Dimidjian K (2004) Datapoints: Trends in naltrexone use among members of a large private health plan. Psychiatric Services 55(3): 221

    Article  PubMed  Google Scholar 

  6. Kranzler HR, Modesto-Lowe V, Van Kirk J (2000) Naltrexone versus nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology 22(5): 493–503

    Article  PubMed  CAS  Google Scholar 

  7. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA, Veterans Affairs Naltrexone Cooperative Study 425 Group (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345(24): 1734–1739

    Article  PubMed  CAS  Google Scholar 

  8. Gastpar M, Bonnet U, Boning J. Mann K. Schmidt LG. Soyka M. Wetterling T. Kielstein V. Labriola D. Croop R (2002) Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol 22(6): 592–598

    Article  PubMed  CAS  Google Scholar 

  9. Pettinanti HM, Oslin D, O’Brien CP (in preparation) A review of all naltrexone clinical trials for alcoholism

    Google Scholar 

  10. Robinson DS, Rickels K (2000) Concerns about clinical drug trials. Journal of Clinical Psychopharmacology 20(6): 593–596

    Article  PubMed  CAS  Google Scholar 

  11. Chan A-W, Hrobjartsson A, Haahr M, Gotzsche PC, Altman DG (2004) Empirical evidence for selective reporting of outcomes in randomized trials. JAMA 291(20): 2457–2465

    Article  PubMed  CAS  Google Scholar 

  12. Thase M (2003) Issues and Ethics. Presented at the Annual American College of Neuropsychopharmacology Annual Meeting, San Juan, Puerto Rico

    Google Scholar 

  13. Koob GF, Rassnick S, Heinrichs S, Weiss F (1994) Alcohol, the reward system and dependence. Exs 71: 103–114

    PubMed  CAS  Google Scholar 

  14. Gonzales RA, Weiss F (1998) Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. The Journal of Neuroscience 18(24): 10663–10671

    PubMed  CAS  Google Scholar 

  15. Gianoulakis C (1996) Implications of endogenous opioids and dopamine in alcoholism: human and basic science studies. Alcohol and Alcoholism 31(1): 33–42

    PubMed  CAS  Google Scholar 

  16. Genazzani AR, Nappi G, Facchinetti F, Mazzella GL, Parrini D, Sinforiani E, Petraglia F, Savoldi F (1982) Central deficiency of beta-endorphin in alcohol addicts. J Clin Endocrinol Metab 55(3): 583–586

    Article  PubMed  CAS  Google Scholar 

  17. Gianoulakis C (1990) Characterization of the effects of acute ethanol administration on the release of beta-endorphin peptides by the rat hypothalamus. Eur J Pharmacol 180: 21–29

    Article  PubMed  CAS  Google Scholar 

  18. King A, Volpicelli J, Frazer A, O’Brien CP (1997) Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology 129: 15–22

    Article  PubMed  CAS  Google Scholar 

  19. Volpicelli JR, Clay KL, Watson NT, O’Brien CP (1995) Naltrexone in the treatment of alcoholism: predicting response to naltrexone. Journal of Clinical Psychiatry 56: 39–44

    PubMed  Google Scholar 

  20. Swift RM, Whelihan W, Kuznetsov O, Buongiorno G, Hsuing H (1994) Naltrexone-induced alterations in human ethanol intoxication. American Journal of Psychiatry151(10): 1463–1467

    PubMed  CAS  Google Scholar 

  21. Davidson D, Palfai T, Bird C, Swift R (1999) Effects of naltrexone on alcohol self-administration in heavy drinkers. Alcohol Clin Exp Res 23(2): 195–203

    PubMed  CAS  Google Scholar 

  22. Volpicelli JR, Rhines KC, Rhines, JS, Volpicelli LA, Alterman, AI, O’Brien CP (1997) Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry 54(8): 737–742

    PubMed  CAS  Google Scholar 

  23. Chick J., Anton R, Checinski K. Croop R. Drummond DC. Farmer R. Labriola D. Marshall J Moncrieff J. Morgan MY. Peters T. Ritson B. (2000) A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol and Alcoholism 35(6): 587–593

    Article  PubMed  CAS  Google Scholar 

  24. O’Malley SS, Krishnan-Sarin S, Farren C, O’Connor PG (2000) Naltrexone-induced nausea patients treated for alcohol dependence: clinical predictors and evidence for opioid-mediated effects. J Clin Psychopharmacol 20(1): 69–76

    PubMed  CAS  Google Scholar 

  25. Wand GS, Mangold, D, El Deiry S, McCaul ME, Hoover D (1998) Family history of alcoholism and hypothalamic opioidergic activity. Arch Gen Psychiatry 55(12): 1114–1119

    PubMed  CAS  Google Scholar 

  26. Kranzler HR, Modesto V, Nuwayser ES (1998) A sustained-release naltrexone preparation for treatment of alcohol dependence. Alcoholism: Clinical and Experimental Research 22(5): 1074–1079

    CAS  Google Scholar 

  27. Kranzler HR, Wesson DR, Billot L for the Drug Abuse Sciences Naltrexone Depot Study Group (2004) Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcoholism: Clinical and Experiment Research 28(7): 1051–1059

    CAS  Google Scholar 

  28. Silverman B (2004) Clinical Trial of Depot Naltrexone. Presented at the American Psychiatry Association Annual Meeting, New York City, New York

    Google Scholar 

  29. Schmidt WK, Tam SW, Shotzberger GS, Smith DH Jr, Clark R, Vernier VG (1985) Nalbuphine. Drug Alcohol Depend 14(3–4): 339–362

    PubMed  CAS  Google Scholar 

  30. Stromberg MF, Casale M, Volpicelli L, Volpicelli JR, O’Brien CP (1998) A comparison of the effects of the opioid antagonists naltrexone, naltrindole, and beta-funaltrexamine on ethanol consumption in the rat. Alcohol 15(4): 281–289

    Article  PubMed  CAS  Google Scholar 

  31. Lee MC, Wagner HN, Tanada S, Frost JJ, Bice AN, Dannals RF (1988) Duration of occupancy of opiate receptors by naltrexone. J Nuclear Med 29(7): 1207–1211

    CAS  Google Scholar 

  32. McCaul ME, Kim WK Wand GS, Bencherif B, Dannals RF, Frost JJ (2004) PET Measurement of μ-and d-opioid receptor availability before and during naltrexone treatment in alcohol dependent subjects (poster). Presented at the Winter Conference on Brain Research, Copper Mountain, Colorado

    Google Scholar 

  33. Tiffany ST (1999) Cognitive concepts of craving. Alcohol Res Health 23(3): 215–224

    PubMed  CAS  Google Scholar 

  34. Monti PM, Rohsenow DJ, Hutchison KE, Swift RM, Mueller TI, Colby SM, Brown RA, Gulliver SB, Gordon A, Abrams DB (1999) Naltrexone’s effect on cue-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res 23(8): 1386–1394

    PubMed  CAS  Google Scholar 

  35. O’Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ (2002) Naltrexone decreases craving and alcohol self-administration in alcohol dependent subjects and activates the hypothalamopituitary-adrenocortical axis. Psychopharmacology 160(1): 19–29

    PubMed  CAS  Google Scholar 

  36. Latt NC, Jurd S, Houseman J, Wutzke SE (2002) Naltrexone in alcohol dependence: a randomized controlled trial of effectiveness in a standard clinical setting. The Medical Journal of Australia 176(11): 530–534

    PubMed  Google Scholar 

  37. Pettinati HM, Volpicelli JR, Pierce JD, O’Brien CP, Pierce JD Jr, (2000) Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis 19(1): 71–83

    Article  PubMed  CAS  Google Scholar 

  38. Jaffe AJ, Rounsaville B, Chang G, Schottenfeld RS, Meyer RE, O’Malley SS (1996) Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. J Consult Clin Psychol 64(5): 1044–1053

    PubMed  CAS  Google Scholar 

  39. Monterosso JR, Flannery BA, Pettinati HM, Oslin DW, Rukstalis M, O’Brien CP, Volpicelli JR (2001) Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 10(3): 258–268

    PubMed  CAS  Google Scholar 

  40. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O’Brien CP (2003) A functional polymorphism of the μ-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28: 1546–1552

    Article  PubMed  CAS  Google Scholar 

  41. Wand GS, Mangold E, El Deiry S, McCaul ME, Hoover D (1998) Family history of alcoholism and hypothalamic opioidergic activity. Arch Gen Psychiatry 55: 1114–1119

    PubMed  CAS  Google Scholar 

  42. Hernandez-Avila C, Wand G, Luo X, Gelernter J, Kranzler H (2003) Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet 118B: 60–65

    Article  PubMed  Google Scholar 

  43. Smolka M. Sander T, Schmidt L, Samochowiec J, Rommelspacher H, Gschiedel N, Wendel B. Hoehe MR (1999) Mu-opioid receptor variants and dopaminergic sensitivity in alcohol withdrawal. Psychoneuroendocrinology 24: 629–638

    Article  PubMed  CAS  Google Scholar 

  44. Kim SG, Kim C-M, Kang D-H, Kim J-K, Byun W-T, Kim S-Y, Park J-M, Kim M-J, Oslin DW (2004) Association of functional opioid receptor genotypes with alcohol dependence in Koreans. Alcohol Clin Exp Res 28(7): 986–990.

    PubMed  CAS  Google Scholar 

  45. McLellan AT, Luborsky L, Woody GE, O’Brien CP (1980) An improved diagnostic evaluation instrument for substance abuse patients: The Addiction severity Index. J Nervous and Mental Disease 168: 26–33

    CAS  Google Scholar 

  46. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, Kampf P, Stracke R, Baehr M, Naber D, Widemann K (2003) Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 60(1): 92–99

    Article  PubMed  CAS  Google Scholar 

  47. Lesch, OM (2004) How to translate the biological basic glutamate mechanisms in preclinical research to human trials and therapy approaches. Presented at the European Winter Conference on Brain Research, Les Arcs, France

    Google Scholar 

  48. Oslin DW, Pettinati H, Volpicelli JR (2002) Alcoholism treatment adherence: older age predicts better adherence and drinking outcomes. Am J Geriatr Psychiatry 19(6); 740–747

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry/Philadelphia Veterans Affairs Medical Center, Treatment Research Center, University of Pennsylvania, 3900 Chestnut Street, Philadelphia, PA, 19104-6178, USA

    Charles P. O’Brien, Helen M. Pettinati & David W. Oslin

Authors
  1. Charles P. O’Brien
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helen M. Pettinati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David W. Oslin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung für Psychopharmakologie, Universit ät Heidelberg, J5, Zentralinstitut für Seelische Gesundheit, 68159, Mannheim, Germany

    Rainer Spanagel

  2. Klinik für Abhängiges Verhalten und Suchtmedizin, J5, Zentralinstitut für Seelische Gesundheit, 68159, Mannheim, Germany

    Karl F. Mann

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Birkhäuser Verlag/Switzerland

About this chapter

Cite this chapter

O’Brien, C.P., Pettinati, H.M., Oslin, D.W. (2005). Naltrexone: clinical data. In: Spanagel, R., Mann, K.F. (eds) Drugs for Relapse Prevention of Alcoholism. Milestones in Drug Therapy MDT. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7305-9_6

Download citation

Publish with us

Policies and ethics

Search

Navigation